Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as Paracetamol fast dissolution suspension
Paracetamol fast dissolution · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Fast dissolution suspension | EXPERIMENTAL | - |
| Medium dissolution suspension | EXPERIMENTAL | - |
| Slow dissolution suspension | EXPERIMENTAL | - |
| Marketed suspension | ACTIVE_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| Paracetamol fast dissolution suspension | DRUG | - |
| Paracetamol medium dissolution suspension | DRUG | - |
| Paracetamol slow dissolution suspension | DRUG | - |
| Paracetamol | DRUG | - |
Inclusion Criteria: * Healthy volunteer * Body Mass Index between 19.0 - 28.0 (kg/m2) inclusive
Paracetamol fast dissolution is an investigational small molecule formulation of paracetamol developed by GSK plc. It is designed as a fast-dissolving suspension, and the only listed trial studied experimental sustained release pediatric suspensions in healthy adult male subjects. No approved indication has been disclosed for this formulation.
Paracetamol fast dissolution is being developed by GSK plc, which trades under the ticker GSK. GSK sponsored the pharmacokinetic study of this formulation. The asset remains in early clinical development under GSK's pipeline.
Paracetamol fast dissolution is in Phase 1 development. One Phase 1 pharmacokinetic trial has been completed, and no active trials are currently listed. The drug is investigational and has not been approved for any indication.
Paracetamol fast dissolution has been studied in one completed Phase 1 trial, NCT01476215, titled a pharmacokinetic study investigating the rate and extent of paracetamol absorption of three experimental sustained release pediatric suspensions. The trial enrolled 18 healthy male subjects in the United States and was active-controlled and randomized.
Yes, Paracetamol fast dissolution suspension is an alternative name for Paracetamol fast dissolution. Both names refer to the same GSK plc investigational formulation studied in the completed Phase 1 pharmacokinetic trial NCT01476215.